Products
Cefepime is commercially available as a powder for solution for injection or infusion (generic). It has been approved in many countries since 2007.
Structure and properties
Cefepime (C19H24N6O5S2, Mr = 480.6 g/mol) is present in drugs as cefepim dihydrochloride monohydrate, a white to yellowish powder that is readily soluble in water.
Effects
Cefepime (ATC J01DE01) has bactericidal properties. It is not hydrolyzed, has low affinity for beta-lactamases, and readily enters Gram-negative pathogens. It is effective against numerous Gram-negative and some Gram-positive bacteria. Effects are based on inhibition of cell wall formation.
Indications
For the treatment of serious bacterial infectious diseases with susceptible pathogens.
Dosage
According to the SmPC. Cefepime is administered intravenously or deeply intramuscularly.
Contraindications
- Hypersensitivity to components of the preparation and beta-lactam antibiotics.
Full precautions can be found in the drug label.
Interactions
Drug-drug interactions are considered unlikely. Cefepime is rarely metabolized.
Adverse effects
The most common potential adverse effects include local injection site reactions, diarrhea, and rash. Rarely, a severe allergic reaction (anaphylaxis) may occur.
